Planning and management to control and eliminate HTLV-1 infection in Iran.
ATL
HAM/TSP
HTLV-1
Prevention
Treatments
Journal
Iranian journal of basic medical sciences
ISSN: 2008-3866
Titre abrégé: Iran J Basic Med Sci
Pays: Iran
ID NLM: 101517966
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
entrez:
17
5
2021
pubmed:
18
5
2021
medline:
18
5
2021
Statut:
ppublish
Résumé
Prevention and treatment of the Human T-cell leukemia virus, type 1 (HTLV-1) which was discovered nearly 40 years ago, still remain challenging. The reported high prevalence of HTLV-1 in some countries around the world triggered an open letter to the World Health Organization (WHO), urging action against HTLV-1 infection in 2018. This highlights the importance of virus elimination strategies to eradicate HTLV-1 infection. In Iran, we have documented our experiences with the virus in order to achieve and promote the possible ways to manage, control, and eliminate HTLV-1. Although there has been considerable progress apropos of HTLV-1, a series of additional challenges need to be tackled to control HTLV-1 infection in Iran.
Identifiants
pubmed: 33995937
doi: 10.22038/ijbms.2021.50803.11562
pmc: PMC8087857
doi:
Types de publication
Journal Article
Langues
eng
Pagination
264-266Références
Blood. 2009 Jun 25;113(26):6528-32
pubmed: 19411628
Lancet Infect Dis. 2019 Jan;19(1):15-16
pubmed: 30587282
PLoS Negl Trop Dis. 2012;6(6):e1675
pubmed: 22720101
J Neuroimmunol. 2012 Sep 15;250(1-2):87-93
pubmed: 22727800
Iran J Basic Med Sci. 2013 Mar;16(3):196-201
pubmed: 24470861
Iran J Basic Med Sci. 2013 Mar;16(3):225-8
pubmed: 24470867
Lancet. 2018 May 12;391(10133):1893-1894
pubmed: 29781438
J Clin Virol. 2011 Nov;52(3):172-6
pubmed: 21840754
BMJ Open. 2016 Apr 26;6(4):e010654
pubmed: 27118288
Adv Ther. 2018 Feb;35(2):135-152
pubmed: 29411267
Virol J. 2017 Jan 30;14(1):14
pubmed: 28137274
AIDS Res Hum Retroviruses. 2012 Sep;28(9):1095-1101
pubmed: 22229796